- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07652515
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer
11 juin 2026 mis à jour par: GlaxoSmithKline
Phase 4, Open Label, Single-arm, Interventional, Multicenter Study to Evaluate the Safety of Dostarlimab in Adult Patients in India With Primary Advanced or Recurrent Endometrial Cancer
This study will evaluate the safety of dostarlimab in combination with carboplatin and paclitaxel followed by monotherapy when administered as a first-line treatment in advanced or recurrent endometrial cancer (EC).
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Estimé)
100
Phase
- Phase 4
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: US GSK Clinical Trials Call Center
- Numéro de téléphone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Sauvegarde des contacts de l'étude
- Nom: EU GSK Clinical Trials Call Center
- Numéro de téléphone: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- Participant with greater than or equals to (>=) 18 years of age, at the time of signing the informed consent.
- Participant has histologically or cytologically proven EC with recurrent or advanced disease.
- Participant must have primary Stage III or Stage IV disease or first recurrent EC with a low potential for cure by radiation therapy or surgery alone or in combination based on investigator's assessment.
- Eligible for dostarlimab treatment according to the approved prescribing information and the investigator's clinical judgement.
- Woman of childbearing potential (WOCBP) agrees to use contraceptive from screening through at least 180 days after the last dose.
- Negative urine pregnancy test at most 24 hours prior to the first dose of study intervention.
- Capable of giving signed informed consent.
- Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria:
- Participant has had greater than (>) 1 recurrence of endometrial cancer.
- Participant has a concomitant malignancy, or participant has a prior non endometrial invasive malignancy who has been disease-free for less than (<) 3 years or who received any active treatment in the last 3 years for that malignancy.
- Participant has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.
- Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection requiring systemic therapy.
- Participant has not recovered adequately from AEs or complications from any major surgery prior to starting therapy.
- Participant has not recovered (i.e., to Grade less than or equal to [<=] 1 or to Baseline) from cytotoxic therapy induced AEs or has received transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte colony-stimulating factor [G-CSF], Granulocyte macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin) within 21 days prior to the first dose of study drug.
- Either the history of hypersensitivity to excipients of the study intervention or to drugs with a similar chemical structure or class of the study intervention.
- Participant has known active hepatitis B (e.g., hepatitis B surface antigen reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid [qualitative] is detected).
Participant has received neo-adjuvant/adjuvant systemic anticancer therapy for primary Stage III or IV disease and:
- has not had a recurrence or Progressive disease (PD) prior to first dose on the study, or
- has had a recurrence or PD within 6 months of completing systemic anticancer therapy treatment prior to first dose on the study.
- Participant has received prior therapy with an anti- Programmed death protein 1 (anti-PD-1), anti- Programmed death ligand 1 (anti-PD-L1), or Programmed death ligand 2 (anti PD L2) agent.
- Participant has received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days or <5 times the half life of the most recent therapy prior to study Day 1, whichever is shorter.
- Systemic glucocorticoids for any purpose other than to manage symptoms of suspected irAEs. If medically deemed necessary (e.g., acute asthma or chronic obstructive pulmonary disease exacerbation, prophylaxis for intravenous (IV) contrast if indicated), Investigators are allowed to use their judgment to treat participants with systemic steroids. In such cases, systemic steroids should be stopped at least 24 hours prior to the next dose of study treatment.
- Participant has received, or is scheduled to receive, a live vaccine within 30 days before first dose of study intervention, during study treatment, and for up to 180 days after receiving the last dose of study intervention.
- Participant has a diagnosis of immunodeficiency and is receiving systemic steroid therapy (>10 milligrams [mg] daily prednisone or equivalent) within 7 days prior to the first dose of the study treatment or is receiving any other form of immunosuppressive medication.
- Participant is currently receiving study intervention, or is enrolled or has participated in any other clinical study involving an investigational intervention and received investigational treatment or used an investigational device within 4 weeks of the first dose of dostarlimab.
- Participant is pregnant or breastfeeding or is expecting to conceive children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of study intervention.
- Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Participants receiving Dostarlimab with Carboplatin + Paclitaxel followed by Dostarlimab Monotherapy
Participants will receive dose level 1 of dostarlimab in combination with carboplatin and paclitaxel followed by dose level 2 of dostarlimab monotherapy.
Dose level 1 is the lowest dose level.
|
Le dostarlimab sera administré.
Le carboplatine sera administré.
Paclitaxel sera administré.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Number of participants with Grade 3 or greater treatment-emergent adverse events (TEAEs) up to Week 49
Délai: Up to Week 49
|
Up to Week 49
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Number of participants with Grade 3 or greater TEAEs up to Week 170
Délai: Up to Week 170
|
Up to Week 170
|
|
Number of participants with TEAEs up to Week 49
Délai: Up to Week 49
|
Up to Week 49
|
|
Number of participants with TEAEs up to Week 170
Délai: Up to Week 170
|
Up to Week 170
|
|
Number of participants with Immune-related adverse events (irAEs) up to Week 49
Délai: Up to Week 49
|
Up to Week 49
|
|
Number of participants with Immune-related adverse events (irAEs) up to Week 170
Délai: Up to Week 170
|
Up to Week 170
|
|
Number of Participants with Serious Adverse Events (SAEs), treatment related Adverse Events (AEs), treatment related SAEs, fatal AEs, non-fatal SAEs up to Week 49
Délai: Up to Week 49
|
Up to Week 49
|
|
Number of Participants with Serious Adverse Events (SAEs), treatment related Adverse Events (AEs), treatment related SAEs, fatal AEs, non-fatal SAEs up to Week 170
Délai: Up to Week 170
|
Up to Week 170
|
|
Number of Participants with AEs leading to discontinuation of treatment, AEs leading to study withdrawal and AEs leading to dose modification up to Week 49
Délai: Up to Week 49
|
Up to Week 49
|
|
Number of Participants with AEs leading to discontinuation of treatment, AEs leading to study withdrawal and AEs leading to dose modification up to Week 170
Délai: Up to Week 170
|
Up to Week 170
|
|
Change from Baseline in hematology parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelet count (Giga cells per Liter) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in hematology parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelet count (Giga cells per Liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in hematology parameter: Red Blood Cell (RBC) count (Trillion cells per Liter) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in hematology parameter: Red Blood Cell (RBC) count (Trillion cells per Liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in hematology parameter: Hemoglobin (Hb) (Grams per Liter) up to Week 49
Délai: Baseline (Day 1) and up to 49
|
Baseline (Day 1) and up to 49
|
|
Change from Baseline in hematology parameter: Hemoglobin (Hb) (Grams per Liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in hematology parameter: Reticulocytes (Percentage of reticulocytes) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in hematology parameter: Reticulocytes (Percentage of reticulocytes) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters) to up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in clinical chemistry parameters: Blood urea nitrogen (BUN), glucose, calcium, sodium, and potassium levels (Millimoles per Liter) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in clinical chemistry parameters: Blood urea nitrogen (BUN), glucose, calcium, sodium, and potassium levels (Millimoles per Liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in clinical chemistry parameters: Total bilirubin, direct bilirubin and creatinine levels (Micromoles per Liter) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in clinical chemistry parameters: Total bilirubin, direct bilirubin and creatinine levels (Micromoles per Liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in clinical chemistry parameters: Total protein levels (Gram per liter) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in clinical chemistry parameters: Total protein levels (Gram per liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels (International units per liter) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels (International units per liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in Vital signs: systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury [mmHg]) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in Vital signs: systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury [mmHg]) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in Vital signs: pulse rate (Beats per minute) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in Vital signs: pulse rate (Beats per minute) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in Vital signs: body temperature (Degrees Celsius) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in Vital signs: body temperature (Degrees Celsius) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in Vital signs: respiratory rate (breaths per minute) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in Vital signs: respiratory rate (breaths per minute) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
|
Change from Baseline in electrocardiogram (ECG) values: Heart rate (Beats per minute) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
|
Baseline (Day 1) and up to Week 49
|
|
Change from Baseline in electrocardiogram (ECG) values: Heart rate (Beats per minute) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
|
Baseline (Day 1) and up to Week 170
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Directeur d'études: GSK Clinical Trials, GlaxoSmithKline
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
17 août 2026
Achèvement primaire (Estimé)
30 août 2030
Achèvement de l'étude (Estimé)
30 août 2030
Dates d'inscription aux études
Première soumission
11 juin 2026
Première soumission répondant aux critères de contrôle qualité
11 juin 2026
Première publication (Réel)
17 juin 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
17 juin 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
11 juin 2026
Dernière vérification
1 juin 2026
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies utérines
- Maladies génitales, femme
- Tumeurs génitales, femme
- Tumeurs utérines
- Tumeurs de l'endomètre
- Produits chimiques organiques
- Hydrocarbures
- Cycloparaffines
- Hydrocarbures, alicyclique
- Hydrocarbures, cyclique
- Terpènes
- Complexes de coordination
- Taxes
- Cyclodécanes
- Diterpènes
- Carboplatine
- Paclitaxel
- dostarlimab
Autres numéros d'identification d'étude
- 309169
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
OUI
Description du régime IPD
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents.
Data sharing is subject to certain criteria, conditions, and exceptions.
For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Délai de partage IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Critères d'accès au partage IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Oui
Étudie un produit d'appareil réglementé par la FDA américaine
Non
produit fabriqué et exporté des États-Unis.
Oui
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .